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Background: The role of allogeneic hematopoietic stem cell transplantation for advanced
indolent lymphoproliferative disorders remains to be established.
Objective: This paper aims to describe the results of allogeneic hematopoietic stem cell
transplantation in patients with advanced indolent lymphoproliferative disorders.
Methods: This article reports on 29 adult patients submitted to allogeneic transplantations
from 1997 to 2010.
Results: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic
leukemia (n = 12). The median age was 44 years (range: 24–53 years) and 65% of patients
were male. Only 21% had had access to rituximab and 45% to ﬂudarabine. All had advanced
disease (stage IV) with partial response or stable disease. Most underwent myeloablative
conditioning n = 17 – 59%). In this scenario, refractory disease was observed in seven (24%)
patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients
(18%). The main cause of death throughout the follow up was refractory disease in six of
the  12 patients who died. Moderate and severe chronic graft-versus-host disease was fre-
quent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival
at  42 months were 56.7% and 45.4%, respectively. According to Kaplan–Meyer analysis, the
median time from diagnosis to transplant predicted the overall survival; however age, gen-
der  and conditioning regimen did not predict the prognosis. It was impossible to reach other
conclusions because of the small sample size in this study.
Conclusions: The role of allogeneic transplantations should be re-evaluated in the era of
targeted therapy.o Bra© 2016 Associac¸ãby  Elsevier Editora Lt
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Table 1 – Patients, disease and transplant characteristcs
(n = 29).
Variable
Gender, n (%)
Male 19 (65%)
Female 10 (34%)
Age, median (range), years 44 (24–53)
Diagnosis, n (%)
Follicular 14 (48%)
CLL/LSC 12 (41%)
Mycosis fungoides 2 (7%)
Hairy cell leukemia 1 (3%)
Ann Arbor Stage IV, n (%) 29 (100%)
Number of prior regimens,  n (%)
≤2 22 (76%)
>2 7 (24%)
Time from diagnosis to HSCT, median (range),
months
24  (8–186)
Disease status at time of transplant,  n (%)
Complete response 7 (24%)
Partial response or stable disease 22 (76%)
Prior radiation 3 (10%)
Prior rituximab 6 (21%)
Prior ﬂudarabine 13 (45%)
Type of donor, n
Matched related donor 28
Unrelated stem cell source 1
Type of conditioning, n (%)
Reduced-intensity 12 (41%)
Myeloablative 17 (59%)
Moderate and severe GVHD, n (%)
Acute 4 (14%)100  rev bras hematol hem
Introduction
Hematopoietic Stem cell transplantation (HSCT) is frequently
considered for eligible patients with non-Hodgkin lymphoma
(NHL).1–6 Autologous HSCT (auto HSCT) is recommended for
patients with either relapsed NHL or those in ﬁrst remission
as consolidative therapy. NHL patients are usually considered
for allogeneic HSCT (allo HSCT) because of the high rate of
relapse seen even after chemotherapy and auto HSCT, and the
potential beneﬁt of a graft-versus-lymphoma (GvL) effect after
allo HSCT. The outcomes for these patients in large prospec-
tive studies are lacking, and current directions and timing of
selection for auto or allo HSCT are inﬂuenced by a variety of
factors, including patient- or disease-related factors, physi-
cian preference, and institutional practices.7–10
Allo HSCT in indolent lymphoproliferative disorders allows
a GvL effect, and the risk of graft contamination by residual
tumor cells is avoided. However, the high transplant-related
mortality (TRM) and nonrelated mortality (NRM) associated
with myeloablative (MA) allo HSCT greatly limits the use of
this approach. Allo HSCT is associated with a lower risk of
relapse, but this reduced risk frequently does not translate
to a survival beneﬁt because of the excessive TRM.11–14 Allo
HSCT has been used as salvage therapy in relapsed lymphoma
after previous auto HSCT; limited success was conﬁned mostly
to patients in remission with good performance status and a
human leukocyte antigen (HLA)-matched sibling donor.15
Reduced-intensity conditioning (RIC) regimens are being
increasingly used in patients with NHL.5,6,16 These lower-
intensity conditioning regimens reportedly have lower NRM,
and can be used in older patients with comorbidities.
Lower-intensity regimens for allo HSCT use lower doses of
conditioning chemotherapy and radiation and rely on an
immune-mediated GvL effect for disease control.17,18 In the
era of emerging novel therapies, the actual timing, optimal
conditioning regimens, and long-term effects of the type of
stem cell transplantation are unclear.
In this scenario, this paper describes the results of allo
HSCT in 29 patients with advanced indolent lymphoprolifera-
tive disorders in two  institutions in Brazil from 1997 to 2010.
Materials  and  Methods
Twenty-nine consecutive over 18-year-old patients with
advanced indolent lymphoproliferative disorders who
received allo HSCT between April 1997 and October 2010
in Hospital São Paulo (Universidade Federal de São Paulo
– UNIFESP) and Hospital Santa Marcelina adult transplant
program, were retrospectively included in this study (Table 1)
by the analysis of patient medical records. Only 21% of the
patients with B cell NHL received planned rituximab-based
chemotherapy before allo HSCT. Patients were required to
have chemotherapy-sensitive disease (or nonbulky stable
disease) documented before allo HSCT and after induction
or salvage chemotherapy. This study was approved by the
Research Ethics Committees of both institutions. All patients
provided informed consent in accordance with the Decla-
ration of Helsinki. Clinical information was reviewed, and
baseline characteristics were recorded, including data ofCLL: Chronic lymphocytic leukemia; LSC: lymphoma of the sper-
matic cord; GVHD: Graft-versus-host disease.
common pre-transplant and transplant variables. All patho-
logic analyses were reviewed, and diagnosis was conﬁrmed
at the institution.
Deﬁnitions  and  response  criteria
Response criteria were based on the guidelines of the Inter-
national Workshop on Non-Hodgkin Lymphoma.18 Complete
remission (CR) was deﬁned as complete radiologic regression
of all previous measurable disease and bone marrow involve-
ment. Partial response (PR) was deﬁned as a reduction of 50%
in the sum of the products of the longest and perpendicu-
lar diameters of measurable lesions. Progression was deﬁned
as an increase of 25% or more  in the sites of lymphoma or
development of new sites of lymphoma at any time after trans-
plantation. Relapse was deﬁned as recurrence of lymphoma
after a complete response. Based on these criteria, all data
were veriﬁed individually regarding the best response status
before HSCT.
Other outcomes analyzed include acute and chronic graft
versus-host disease (GVHD) and cause of death. Acute GVHD
(aGVHD) was deﬁned and graded based on the pattern and
severity of organ involvement using established criteria.19
Chronic GVHD (cGVHD) was deﬁned as the development of any
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Table 2 – Mortality within 100 days after transplant.
Patient 1 2 3 4 5
Age (years) 50 46 47 24 41
Gender M F F M M
Disease Follicular Lymphocytic Follicular CLL Follicular
Time from diagnosis to
transplant (months)
25  186 16 28 14
Conditioning CyMel CyMel FluTBI CyTBI FluTBI
Disease status Refractory Refractory Refractory Refractory Refractory
Infection VRE, candidemia none none Fusarium Pseudomonas
Days to death after transplant 32 33 24 53 81
Cause of death Gastrointestinal
bleeding, sepsis
Lung bleeding VOD Sepsis perforated acute
abdomen caused by
necrosis of the tumor
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p-value = 0.290, respectively). Only less time between the diag-
nosis and transplantation improved the OS (p-value = 0.031 –
Figure 2). The median time from diagnosis to transplant was
two years (range: 8–186 months). Younger patients have better
Table 3 – Acute graft-versus-host disease in 29 patients.
Site Grade I–IV Grade III or IVM: male; F: female; CyMel: cytarabine and melphalan; FluTBI: ﬂudara
vancomycin-resistant enterococci; VOD: venous oclusive disease.
hronic GVHD based on clinical criteria.20,21 Both these events
ere summarized by the corresponding cumulative incidence
stimate, with death without the development of GVHD as the
ompeting risk. The World Health Organization criteria were
sed to deﬁne the histologic classiﬁcation of NHL after 2001.
ransplant  procedures
hirteen patients received RIC [ﬂudarabine and total body
rradiation (n = 9), ﬂudarabine and cyclophosphamide (n = 2),
udarabine and busulfan (n = 1) or carmustine, etoposide,
ytarabine and melphalan – BEAM (n = 1)], and 16 received a MA
egimen [cyclophosphamide and melphalan (n = 8), busulfan
nd cyclophosphamide (n = 6), or cyclophosphamide and total
ody irradiation (n = 2)]. There was only one unrelated donor
tem cell transplantation. All patients received GVHD prophy-
axis with a calcineurin inhibitor and either methotrexate (MA
egimen) or mycophenolate mofetil (RIC regimen).
upportive  care
ll patients received standard supportive care as per
nstitutional guidelines. Standard antimicrobial prophylaxis,
urveillance cultures, and treatment were administered as per
rotocol.
tatistical  analysis
ariables are described as medians and range for con-
inuous variables, and percentage of total for categorical
ariables (Table 1). Occurrence of acute and chronic GVHD,
elapse and mortality were calculated using cumulative
ncidence estimates, adjusted for the competing risk. Prob-
bilities of progression free survival (PFS) and overall survival
OS) were estimated from the time of transplantation using
aplan–Meier analysis. Univariate analysis was performed
ith disease and transplant-related variables to see the effect
n long-term outcome of patients. The chi-square test was
sed to determine the relationship between all categorical
ariables. The Mann–Whitney U rank sum test was used to
dentify associations between continuous variables and cat-
gories. All reported p-values are two-sided with statisticaland total body irradiation; CLL: chronic lymphocytic leukemia; VRE:
signiﬁcance declared at a p-value <0.05. Statistical analyses
were performed using the Statistical Package for the Social
Sciences software (version 20; IBM-SPSS, Chicago, IL, USA).
Results
Variables related to the patient, disease, and transplant out-
comes are presented in Table 1. Twenty-nine eligible patients
who underwent allo HSCT for advanced indolent lympho-
proliferative disorders from January 1997 to December 2010
were included in this analysis. The median age was 44 years
(range: 24–53 years). Half of the patients had follicular NHL. All
patients were staged as Ann Arbor IVA or IVB. Most patients
received less than three therapeutic regimens before allo
HSCT, and only 21% had received rituximab. The median time
from diagnosis until transplant was 24 months. Seventy-six
percent of patients had partial response or stable disease at
the time of the transplant. MA conditioning was used in 59%,
especially in the ﬁrst years of this study.
TRM was associated with refractory disease in the ﬁve
patients that died before 100 days (Table 2). Sixteen patients
had some grade of cutaneous, hepatic and gastrointestinal
aGVHD, but only four had grade III or IV (Table 3). Of 24
patients, 18 had cGVHD, although just 12 with moderate
or severe one. Four died of infection or other immunosup-
pression complications (Table 4). The OS and disease free
survival (DFS) at 42 months were 56.7% and 45.4%, respec-
tively (Figure 1). Age, gender, and conditioning regimen had
no impact on the OS (p-value = 0.0091, p-value = 0.123 andCutaneous 8 2
Hepatic 8 3
Gastrointestinal tract 7 1
Total 16 (55%) 4 (14%)
102  rev bras hematol hemoter. 2 0 1 6;3 8(2):99–105
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Figure 1 – Overall and disease free survival in advanced lymphoproliferative disorders and non-Hodgkin lymphoma after
allogeneic hematopoietic stem cell transplantation.
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Figure 2 – Impact of age, gender, time of disease and conditioning on the overall survival.
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Table 4 – Outcomes at ﬁve years of 24 patients in relation
with chronic graft-versus-host disease (GVHD).
GVHD
No (n = 6) Alive n = 3
Dead n = 3 Day + 129 (pneumonia)
Day + 218 (refractory, pneumonia)
Day + 1280 (myocardial infarction)
Yes (n = 18) Alive n = 14 No treatment n = 3
Under treatment n = 11
Dead n = 4 Day + 244 (refractory, sepsis)
Day + 324 (severe pulmonary chronic
GVHD, pneumonia)
Day + 343 (accident on passage of
catheter)
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deacetylase and immunomodulators gain U.S. FDA approvalDay + 555 (chronic renal failure,
infection)
S and men  had better responses than women (p-value >0.05
or both).
iscussion
n the present study, 29 patients with advanced indolent lym-
hoproliferative disorders were analyzed after allo HSCT in
wo transplant centers in Brazil between April 1997 and Octo-
er 2010. About 42 months after the transplant, 56.7% were
live and the DFS was 45.4%.
Indolent lymphoproliferative disorders, mainly NHL, com-
rise a variety of diseases with different incidence patterns
n populations. Approximately 390,000 new cases and 199,000
HL deaths were estimated in the world in 2012. There were
800 new cases just in Brazil in 2014, that is, about ﬁve new
ases for every 100,000 inhabitants.22 Like most cancers, the
isk of NHL increases with age, often when patients are unable
o get HSCT.
Generally, treatment of indolent NHL in Brazil is through
he National Health System. According to the census depart-
ent of the Brazilian Government, the Instituto Nacional de
eograﬁa e Estatística (IBGE), the coverage of health insurance
n Brazil is 24.7%. This cover is concentrated regionally, with
4% of insurance in 2012 being in the southeast.23 There is
 delay in the consolidation of the use of new medicines in
he Brazilian NHS. Rituximab, for example, widely used in
atients with indolent CD20+ NHL, was approved by the U.S.
ederal and Drugs Administration (FDA) in 1998. In Brazil, the
uthorization to routinely use this drug was only published in
009.24–26
Registry data from the European Society for Blood and
arrow Transplantation (EBMT) and the Center for Interna-
ional Blood and Marrow Transplant Research (CIBMTR) show
o plateau in relapse rates after autografting.11,27,28 Further-
ore,  the risk of second malignancies after auto HSCT is
ot insigniﬁcant, ranging from 5% to 15% in several stud-
es. Clinical evidence of a GvL effect after allo HSCT is
uggested by a plateau in relapse risk that is reached 2–5
ears following allo HSCT, indicating that a substantial pro-
ortion of lymphoma patients get long-term disease control
10–12 years), and relapses are uniformly low. Even patients
ith refractory or relapsed lymphoproliferative disorders are 0 1 6;3 8(2):99–105 103
beneﬁted with allo HSCT. Early allo HSCT produces better OS
and PFS rates. However, allo HSCT increases post-transplant
complications, such as cGVHD. The timing to perform allo
HSCT in these patients is not well deﬁned.29–31 The CIBMTR
observed good results in patients with NHL submitted the allo
HSCT. On analyzing 1248 over 40-year-old patients after RIC or
non-myeloablative regimens (NMA) for aggressive (n = 668) or
indolent NHL (n = 580), it was noted that allo HSCT is a good
therapeutic option even for over 55-year-old patients, giving
an OS of 40% in three years. There is an increase in prolonged
remission; the report concluded that allo HSCT is underused
in this group of patients.32
In the cohort of advanced indolent lymphoproliferative dis-
order patients of this study, only the time from diagnosis to
transplant was signiﬁcantly important (p-value = 0.031). The
median time from diagnosis to transplant was two  years. The
therapeutic option of allo HSCT in these patients was only
for advanced disease. A fact that may have contributed to the
delay in time from diagnoses to transplant was the increased
use of rituximab and possible transient disease control. At the
beginning of this study, when rituximab was less available,
patients were treated with ﬁrst line therapy, and according
to indication, were directly referred for transplant. In the later
years, the patients tried to receive rituximab through the court
of justice, thereby postponing the transplant.
Younger patients had better, albeit not statistically sig-
niﬁcant, responses than older patients. Women had worse
results than men, but again without statistical signiﬁcance.
This could indicate that men  have better home care than
women, in this group.
The conditioning was MA in 59% of patients. This repre-
sents the period of transition from using MA to RIC in Brazil.
TRM was associated with refractory disease in the ﬁve patients
that died before 100 days than the refractoriness was  the
most common cause of transplant failure especially in the
last years of this study when the RIC had become routine in
transplant centers. There was an increase in allo HSCT for
refractory and long-term disease, particularly with the possi-
bility of performing transplants in the elderly and in patients
with comorbidities. The beneﬁts that could have been visible
with the decrease of the NRM, ended up being masked by the
change in the proﬁle of transplant patients. Possibly RIC was
not enough to treat refractory disease in these cases. A MD
Anderson study showed excellent DFS and OS (85% and 83%,
respectively) after a median follow-up of ﬁve years for relapsed
follicular NHL after RIC using ﬂudarabine, cyclophosphamide
and rituximab followed by allo HSCT. The incidences of grade
II–IV acute and chronic GVHD were 11% and 0%, respectively.
They analyzed 47 indolent NHL patients submitted to allo
HSCT from March 1999 to April 2005.17
At the start of immunochemotherapy, most patients had
no access to these medicines. It remains to be seen what the
response will be after the regular use of these drugs as ﬁrst line
treatment and access to transplant in accordance with insti-
tutional standard protocols. It is certain that, as agents that
target pathways such as phosphoinositide (PI) kinase, histonefor various NHL histologies, the role of timing of HSCT will
become even more  complex. Incorporating these agents as
maintenance strategies following RIC and allo HSCT or even
oter
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auto HSCT is certainly very attractive. We  believe that future
clinical trials should aim to consider these novel agents in the
transplant and after the transplant period.
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